Home/Pipeline/EI-012

EI-012

Solid tumor cancer

PreclinicalActive

Key Facts

Indication
Solid tumor cancer
Phase
Preclinical
Status
Active
Company

About Elixiron Immunotherapeutics

Taiwan biotech delivering precision immunotherapies for neurodegeneration, autoimmunity, and cancer via mRNA and antibody platforms.

View full company profile

Other Solid tumor cancer Drugs

DrugCompanyPhase
Deoxymab Oncology CandidatePatrysPreclinical